ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.599,57
-0,46%
S&P 500
5.222,68
0,16%
US Dollar vs BRL
5,1568
0,37%
Bitcoin
61.189,36
0,64%
Brent Oil
82,585
0,00%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Alnylam Pharmaceuticals Inc (ALNY)

  7. Alnylam Pharmaceuticals Inc (ALNY) Notícias

ALNY

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALNY
DataHoraFonteTítuloCódigoCompanhia
07/05/202409:00Business WireAlnylam Issues 2023 Corporate Responsibility ReportNASDAQ:ALNYAlnylam Pharmaceuticals Inc
02/05/202409:00Business WireAlnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period ActivityNASDAQ:ALNYAlnylam Pharmaceuticals Inc
30/04/202408:00PR Newswire (Canada)Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including AustraliaNASDAQ:ALNYAlnylam Pharmaceuticals Inc
18/04/202409:00Business WireAlnylam to Webcast Conference Call Discussing First Quarter 2024 Financial ResultsNASDAQ:ALNYAlnylam Pharmaceuticals Inc
07/04/202409:00Business WireAlnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled HypertensionNASDAQ:ALNYAlnylam Pharmaceuticals Inc
20/03/202409:00Business WireAlnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific SessionNASDAQ:ALNYAlnylam Pharmaceuticals Inc
13/03/202408:30Business WireAlnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive DiseaseNASDAQ:ALNYAlnylam Pharmaceuticals Inc
06/03/202408:50Business WireAlnylam meldet positive KARDIA-2 Topline-Studienergebnisse, die eine klinisch signifikante Blutdrucksenkung bei Zugabe von Zilebesiran zu Standard-Blutdrucksenkern belegenNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/03/202419:39Business WireAlnylam annonce des résultats positifs de l’étude KARDIA-2 démontrant des réductions cliniquement significatives de la pression artérielle lorsque le zilebesiran est ajouté à des antihypertenseurs standardsNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/03/202418:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/03/202409:30Business WireAlnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care AntihypertensivesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
04/03/202418:33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALNYAlnylam Pharmaceuticals Inc
29/02/202418:00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
27/02/202410:30Business WireAlnylam to Webcast Presentations at Upcoming March Investor ConferencesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
15/02/202418:23Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ALNYAlnylam Pharmaceuticals Inc
15/02/202410:00Business WireAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period ActivityNASDAQ:ALNYAlnylam Pharmaceuticals Inc
09/02/202420:14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALNYAlnylam Pharmaceuticals Inc
29/01/202410:00Business WireAlnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ALNYAlnylam Pharmaceuticals Inc
09/01/202410:05Business WireAlnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen’s AssociationNASDAQ:ALNYAlnylam Pharmaceuticals Inc
07/01/202420:00Business WireAlnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional UpdatesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
02/01/202409:30Business WireAlnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ALNYAlnylam Pharmaceuticals Inc
13/12/202309:30Business WireAlnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D DayNASDAQ:ALNYAlnylam Pharmaceuticals Inc
06/12/202310:00Business WireAlnylam to Webcast Virtual R&D DayNASDAQ:ALNYAlnylam Pharmaceuticals Inc
30/11/202310:00Business WireAlnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023NASDAQ:ALNYAlnylam Pharmaceuticals Inc
12/11/202314:08Business WireAlnylam präsentiert positive Ergebnisse der Phase-2-Dosisfindungsstudie KARDIA-1 zu Zilebesiran, einem RNAi-Prüftherapeutikum zur Behandlung von Bluthochdruck bei Patienten mit hohem kardiovaskulärem RisikoNASDAQ:ALNYAlnylam Pharmaceuticals Inc
12/11/202314:08Business WireAlnylam présente des résultats positifs de l'étude KARDIA-1 de Phase 2 de détermination de la dose évaluant zilebesiran, un traitement iARN expérimental en développement pour le traitement de l'hypertension chez les patients à risque...NASDAQ:ALNYAlnylam Pharmaceuticals Inc
11/11/202318:00Business WireAlnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular RiskNASDAQ:ALNYAlnylam Pharmaceuticals Inc
07/11/202310:00Business WireAlnylam to Webcast Presentations at Upcoming November Investor ConferencesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
02/11/202309:22Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALNYAlnylam Pharmaceuticals Inc
02/11/202309:00Business WireAlnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period ActivityNASDAQ:ALNYAlnylam Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALNY

Seu Histórico Recente

LSE
0HF9
Amicus Therapeutics
TSXV
GBN
Golden Band Resources Inc.
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados